CRISPR THERAPTC (NASDAQ:CRSP) Director Kurt Von Emster sold 55,569 shares of CRISPR THERAPTC stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $19.59, for a total value of $1,088,596.71. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Kurt Von Emster also recently made the following trade(s):

  • On Tuesday, August 8th, Kurt Von Emster sold 35,473 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $18.63, for a total value of $660,861.99.
  • On Friday, August 4th, Kurt Von Emster sold 50,477 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $17.81, for a total value of $898,995.37.
  • On Tuesday, August 1st, Kurt Von Emster sold 5,512 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $17.51, for a total value of $96,515.12.
  • On Friday, July 28th, Kurt Von Emster sold 41,312 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $17.63, for a total value of $728,330.56.
  • On Wednesday, July 26th, Kurt Von Emster sold 32,930 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $17.60, for a total value of $579,568.00.
  • On Friday, July 14th, Kurt Von Emster sold 69,859 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $16.84, for a total value of $1,176,425.56.
  • On Wednesday, July 12th, Kurt Von Emster sold 31,992 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $16.56, for a total value of $529,787.52.
  • On Wednesday, July 5th, Kurt Von Emster sold 4,254 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $16.26, for a total value of $69,170.04.
  • On Thursday, June 29th, Kurt Von Emster sold 43,202 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $16.90, for a total value of $730,113.80.
  • On Tuesday, June 27th, Kurt Von Emster sold 81,435 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $17.08, for a total value of $1,390,909.80.

CRISPR THERAPTC (CRSP) traded down 2.53% during mid-day trading on Wednesday, hitting $18.86. The stock had a trading volume of 142,912 shares. The stock has a 50 day moving average of $17.24 and a 200-day moving average of $17.49. The firm’s market cap is $752.42 million. CRISPR THERAPTC has a 1-year low of $11.63 and a 1-year high of $25.00.

CRISPR THERAPTC (NASDAQ:CRSP) last announced its quarterly earnings data on Thursday, August 10th. The company reported ($0.56) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.62) by $0.06. The firm had revenue of $3.60 million for the quarter, compared to analyst estimates of $3.29 million. CRISPR THERAPTC had a negative return on equity of 47.46% and a negative net margin of 406.61%. The firm’s revenue was up 350.0% compared to the same quarter last year. Analysts predict that CRISPR THERAPTC will post ($2.43) EPS for the current fiscal year.

WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/08/16/insider-selling-crispr-theraptc-crsp-director-sells-55569-shares-of-stock.html.

A number of analysts have recently commented on the company. Cann assumed coverage on CRISPR THERAPTC in a research note on Monday, July 17th. They issued a “market perform” rating on the stock. Chardan Capital reissued a “buy” rating on shares of CRISPR THERAPTC in a research note on Monday. SunTrust Banks, Inc. assumed coverage on CRISPR THERAPTC in a research note on Thursday, July 13th. They issued a “hold” rating and a $16.00 price objective on the stock. Finally, Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of CRISPR THERAPTC in a research note on Tuesday, July 18th. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. CRISPR THERAPTC currently has an average rating of “Buy” and an average price target of $21.92.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP raised its position in shares of CRISPR THERAPTC by 0.4% in the first quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock worth $16,272,000 after buying an additional 3,070 shares during the last quarter. IHT Wealth Management LLC purchased a new position in shares of CRISPR THERAPTC during the first quarter worth approximately $110,000. Wells Fargo & Company MN raised its position in shares of CRISPR THERAPTC by 459.7% in the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock worth $128,000 after buying an additional 6,560 shares during the last quarter. ARK Investment Management LLC purchased a new position in shares of CRISPR THERAPTC during the second quarter worth approximately $206,000. Finally, Monashee Investment Management LLC raised its position in shares of CRISPR THERAPTC by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock worth $473,000 after buying an additional 15,000 shares during the last quarter. Hedge funds and other institutional investors own 24.08% of the company’s stock.

CRISPR THERAPTC Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for CRISPR THERAPTC (NASDAQ:CRSP)

Receive News & Ratings for CRISPR THERAPTC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR THERAPTC and related companies with MarketBeat.com's FREE daily email newsletter.